Cargando…

The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially emerging variants, poses an increased threat to global public health. The significant reduction in neutralization activity against the variants such as B.1.351 in the serum of convalescent patients and vaccinated people calls f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Longbo, Xu, Yuhua, Wu, Liping, Feng, Jin, Zhang, Lu, Tang, Yongjie, Zhao, Xiang, Mai, Runming, Chen, Liyun, Mei, Lingling, Tan, Yuanzhen, Du, Yingying, Zhen, Yanping, Su, Wenhan, Peng, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146450/ https://www.ncbi.nlm.nih.gov/pubmed/35632595 http://dx.doi.org/10.3390/v14050854

Ejemplares similares

Novel Highly Divergent SARS-CoV-2 Lineage With the Spike Substitutions L249S and E484K
por: Laiton-Donato, Katherine, et al.
Publicado: (2021)

Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse
por: Du, Yingying, et al.
Publicado: (2021)

A Pseudovirus-Based Entry Assay to Evaluate Neutralizing Activity against Respiratory Syncytial Virus
por: Hu, Longbo, et al.
Publicado: (2023)

Limited spread of a rare spike E484K-harboring SARS-CoV-2 in Marseille, France
por: Colson, Philippe, et al.
Publicado: (2022)

E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil
por: Ferrareze, Patrícia Aline Gröhs, et al.
Publicado: (2021)

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
por: Jangra, Sonia, et al.
Publicado: (2021)

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
por: Jangra, Sonia, et al.
Publicado: (2021)

E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody
por: Chakraborty, Sandipan
Publicado: (2022)

Emergence in southern France of a new SARS-CoV-2 variant harbouring both N501Y and E484K substitutions in the spike protein
por: Colson, Philippe, et al.
Publicado: (2022)

Thermal Reactivity of Neutral and Oxidized Ferrocenyl-Substituted Enediynes
por: Cinar, Mehmet Emin, et al.
Publicado: (2014)

Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit
por: Hurlburt, Nicholas K., et al.
Publicado: (2022)

Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil
por: Nonaka, Carolina K. V., et al.
Publicado: (2021)

Characterization of intrinsic and effective fitness changes caused by temporarily fixed mutations in the SARS-CoV-2 spike E484 epitope and identification of an epistatic precondition for the evolution of E484A in variant Omicron
por: Schröder, Simon, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera
por: Xie, Xuping, et al.
Publicado: (2021)

The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera
por: Li, Gen, et al.
Publicado: (2021)

A new intracellular targeting motif in the cytoplasmic tail of the spike protein may act as a target to inhibit SARS-CoV-2 assembly
por: Hu, Longbo, et al.
Publicado: (2023)

Cell-death-inducing DFFA-like Effector B Contributes to the Assembly of Hepatitis C Virus (HCV) Particles and Interacts with HCV NS5A
por: Cai, Hua, et al.
Publicado: (2016)

Recombinant subunits of SARS‐CoV‐2 spike protein as vaccine candidates to elicit neutralizing antibodies
por: Noorabad Ghahroodi, Faezeh, et al.
Publicado: (2022)

Insights into the structure and dynamics of SARS-CoV-2 spike glycoprotein double mutant L452R-E484Q
por: Ahamad, Shahzaib, et al.
Publicado: (2022)

484 Allergen Standardisation in Allergens and Allergoids—Challenges and Considerations
por: Skinner, Murray, et al.
Publicado: (2012)

MON-484 Thyroid Nodules: Not so Simple to Manage
por: Cruz, Alegyari Figueroa, et al.
Publicado: (2020)

Emergence of OXA-484-Producing Klebsiella variicola in China
por: Ge, Haoyu, et al.
Publicado: (2023)

A one-step real-time RT-PCR assay for simultaneous typing of SARS-CoV-2 mutations associated with the E484K and N501Y spike protein amino-acid substitutions
por: Chaintoutis, Serafeim C., et al.
Publicado: (2021)

SUN-484 Complex Thyroid Cancer with Several Recurrences and Metastases
por: Patel, Kruti K, et al.
Publicado: (2020)

miR-484: A Potential Biomarker in Health and Disease
por: Jia, Yin-zhao, et al.
Publicado: (2022)

FF(483–484) motif of human Polη mediates its interaction with the POLD2 subunit of Polδ and contributes to DNA damage tolerance
por: Baldeck, Nadège, et al.
Publicado: (2015)

Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage
por: Álvarez-Díaz, Diego A., et al.
Publicado: (2022)

A spike protein S2 antibody efficiently neutralizes the Omicron variant
por: Hu, Jia, et al.
Publicado: (2022)

The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals
por: Uwamino, Yoshifumi, et al.
Publicado: (2022)

A discernable increase in the severe acute respiratory syndrome coronavirus 2 R.1 lineage carrying an E484K spike protein mutation in Japan
por: Sekizuka, Tsuyoshi, et al.
Publicado: (2021)

Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual
por: Halfmann, Peter J, et al.
Publicado: (2022)

Quantitative comparison of the efficiency of antibodies against S1 and S2 subunit of SARS coronavirus spike protein in virus neutralization and blocking of receptor binding: Implications for the functional roles of S2 subunit
por: Zeng, Fanya, et al.
Publicado: (2006)

435. Outcomes for E484K Mutation Negative COVID-19 Patients Cohorted with E484K Mutation Positive COVID-19 Patients: A Retrospective Cohort Study
por: Buskandar, Fahad, et al.
Publicado: (2021)

Conservation of Neutral Substitution Rate and Substitutional Asymmetries in Mammalian Genes
por: Mugal, C.F., et al.
Publicado: (2010)

Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes
por: Cheng, Lin, et al.
Publicado: (2021)

miR-484 is associated with disease recurrence and promotes migration in prostate cancer
por: Lee, Daniel, et al.
Publicado: (2020)

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine
por: He, Yuxian, et al.
Publicado: (2004)

Emergence of SARS-CoV-2 Variant B.1.575.2, Containing the E484K Mutation in the Spike Protein, in Pamplona, Spain, May to June 2021
por: Trobajo-Sanmartín, Camino, et al.
Publicado: (2021)

Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q
por: Wilhelm, Alexander, et al.
Publicado: (2021)

A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV
por: Mitsuki, Yu-ya, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_423ks8v6nmlv6do5loq1stm2dq